More on CLRBW
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.13 |
|
|||
| Open | $0.88 | ||||
| 52 Wk High | $1.40 | ||||
| 52 Wk Low | $0.11 | ||||
| Day High | $0.13 | ||||
| Day Low | $0.13 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 214,095 | ||||
- Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
- Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
- Cellectar reports 12-month data for cancer drug in rare blood disorder
- Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
- Cellectar Biosciences raises up to $140 million in oversubscribed financing
- Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
- Cellectar enrolls first patient in breast cancer drug trial
- Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
- Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research
- Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Entities mentioned with CLRBW
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Ladenburg Thalmann Financial Services | View Related Stories »
- Dividend | View Related Stories »
- Balyasny Asset Management | View Related Stories »
- S3 | View Related Stories »
- Twitter | View Related Stories »
- S1 | View Related Stories »
- Show More...
